NCT04699630 - A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

April 9, 2025

Study Completion Date

April 9, 2025

Conditions

Metastatic Breast CancerLocally Advanced Breast Cancer

Interventions

DRUG

U3-1402

All subjects will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 of every 3 weeks. One cycle is defined as 3 weeks.

Trial Locations (11)

Levine Cancer Institute, Charlotte

Florida Cancer Specialists-North, St. Petersburg

Florida Cancer Specialists-South, Fort Myers

University of Alabama at Birmingham, Birmingham

SCRI Oncology Partners, Nashville

Tennessee Oncology, Nashville

Washington University School of Medicine, St Louis

Highlands Oncology Group, Springdale

City of Hope, Duarte

Seattle Cancer Care Alliance, Seattle

Rutgers-Cancer Institute of New Jersey, New Brunswick